No Direct Interaction Found
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, has no documented interactions with COVID-19 vaccine types in clinical data or labeling. Dosing remains 300 mg subcutaneous every 4 weeks (after loading doses) regardless of mRNA (Pfizer/Moderna), viral vector (J&J/AstraZeneca), or protein subunit (Novavax) vaccines.[1][2]
Vaccine Response in Cosentyx Patients
Patients on Cosentyx mount adequate antibody responses to COVID-19 vaccines, similar to non-immunosuppressed individuals. Studies show seroconversion rates of 90-100% post-mRNA vaccination, with no need for dose adjustments. Live-attenuated vaccines are avoided due to immunosuppression risk, but COVID-19 vaccines are non-live.[3][4]
Why No Dosing Changes?
Cosentyx targets IL-17, sparing broad immune suppression unlike JAK inhibitors or high-dose steroids. Real-world data from over 1,000 patients confirms stable vaccine immunogenicity without altering Cosentyx regimens.[5]
Timing Recommendations
Administer COVID-19 vaccines anytime relative to Cosentyx doses—booster timing aligns with standard schedules. Rheumatology guidelines (ACR, EULAR) endorse vaccination without interrupting therapy.[6]
Patient Concerns and Exceptions
Rare cases of reduced response occur in patients with multiple comorbidities or concurrent immunosuppressants. Monitor for breakthrough infections; no evidence vaccine type influences Cosentyx efficacy or safety.[7]
[1]: Novartis Cosentyx Prescribing Information
[2]: Drugs.com Cosentyx Interactions
[3]: Annals of Rheumatic Diseases: Vaccine Response in IL-17 Inhibitors (2022)
[4]: JAMA Dermatology: Seroconversion in Psoriasis Patients (2021)
[5]: Rheumatology: Real-World Immunogenicity Data (2023)
[6]: ACR COVID-19 Vaccine Guidance
[7]: CDC Immunocompromised Vaccine FAQ